WuXi Chemistry’s Post

Very unusual phosphine oxide functionality in aleniglipron (GLP-1R agonist).

Reaction Biology recently collaborated with Mayo Clinic and EyePoint Pharmaceuticals, on a study comparing the anti-angiogenic potential of pan-VEGFR tyrosine kinase inhibitors to uncover their therapeutic potential. Learn how our best-in-class HotSpot™ radiometric assay supported key findings on this paper 📃Read the publication on PLOS: https://hubs.ly/Q02Nn39g0 🔬Discover HotSpot™ Kinase Assay: https://hubs.ly/Q02Nn3ll0 #angiogenesis #kinaseinhibitor #VEGFR

Check out this article! Our experts Krishnendu Khan, Ph.D. and Rui Li share their insights to better understand how to select cryo containers that meet the specific needs of your cryopreservation application and safeguard the #celltherapy! #Biotechnology #Biologics

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the last healthy subject in the multiple ascending dose (MAD) part of its Phase 1 study has completed the highest planned dose levels. No discontinuations or serious adverse events were reported. After database lock, topline data from this Phase 1, randomized, double-blind, placebo-controlled study is expected to be released in August, and full safety analysis and plasma pharmacokinetics are expected to be presented at a future congress.

As cell therapy is becoming mainstream, packaging strategies to bring these life saving drugs to patients without loosing its potency are also evolving. Cryo-preservation post manufacturing is an important step in this process and it is critical to select a right container system for that. Checkout this article from Rui Li and me where we discuss about the ideal container characteristics for cell therapy applications. #celltherapy #cryopreservation #primarycontainer

Day 1: Working on #oligonucleotide-based therapies? Connect with our WuXi TIDES team at the 9th OPT Congress in Boston from March 13-14. On March 13 at 12:45 pm EST, Yvonne Angell, Ph.D., our Executive Director and Head of TIDES discovery project management, will outline the technical challenges encountered in the discovery phase of oligonucleotide therapeutics. Through two case studies, we’ll detail our strategies for advancing programs from discovery to development, addressing technical obstacles and optimizing our approach. This presentation will offer practical insights for navigating the complexities of oligonucleotide therapy development.   Schedule a meeting with our team: [email protected] Learn more: https://lnkd.in/g6AmChYd #WuXiTIDES #peptides #oligonucleotides #CRDMO

📢 @Antag Therapeutics is pleased to announce #FDA IND clearance for AT-7687, our lead molecule for the treatment of #obesity.   AT-7687 is a peptide GIP receptor antagonist, designed for once-weekly subcutaneous administration. Preclinical studies have demonstrated that AT-7687 attenuates weight gain and enhances GLP-1-mediated weight loss while also improving lipid profiles, particularly LDL, independently of weight changes.   Our phase I clinical trial will evaluate the safety, tolerability, and pharmacokinetics of AT-7687, both as a monotherapy and in combination with #semaglutide, in healthy lean and healthy obese participants.   This is a significant milestone for #AntagTherapeutics, and we look forward to updating you as we progress AT-7687 through clinical development.   Read the full press release, linked in the comments below.   #clinicalupdate #INDclearance #GIP

The hotly anticipated 2nd RNA Assay Development & Screening Summit returns to Boston, August 20-22, 2024, to revolutionize RNA-targeted drug discovery with robust assays and screens. Check out the Brand-New Event Guide here: https://ter.li/zuknlg Don’t miss your opportunity to see expert talks with industry leaders from AstraZeneca, Arrakis Therapeutics, Biogen, NextRNA Therapeutics, Accent Therapeutics, Inc. , Atavistik Bio and many more, at the industry's first and only conference dedicated to supporting in-house assay development and screening strategies for discovering selective RNA-targeting small molecules. #RNAtargeting #RNA #smallmolecules #drugdiscovery #assaydevelopment #assay #screening

Achieving Next-Generation mRNA-LNP Therapeutics Delivery https://lnkd.in/e_H8yJEJ Three LNP experts (Dr. Kate Zhang, Professor Ben Muir, and Dr. Sumit Luthra) parse out the current opportunities and unknowns facing the development of next-generation LNPs.

Interested in learning more about icIEF fractionation followed by mass spec? We have a webinar next week, on June 20th, with Lan Li from Amgen and Amreen Jonas from Mersana Therapeutics. You can use the link below to register. I am very excited about this one! #MassSpec